Fleming Harold Edward 4

What Happened Harold E. Fleming, a director of Upstream Bio, Inc. (UPB), was granted a derivative award on 2026-06-09 covering 17,096 shares with a reported price of $0.00 (no cash paid at grant). The filing reports this as an option/award (derivative instrument), not an open-market purchase or sale, so no immediate cash value was exchanged and no shares were sold.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-11 (filed within the standard two-business-day window).
• Award: 17,096 shares reported as a derivative grant at $0.00.
• Shares owned after transaction: not specified in the provided filing.
• Footnote F1 (vesting): the option vests in full upon the earlier of (i) June 9, 2027 or (ii) the next Annual Meeting of Stockholders, subject to Fleming's continued service.
• Footnote F2 (ownership): Fleming agreed to receive and hold the securities for the benefit of Enavate Sciences, LP and disclaims beneficial ownership and all right, title and interest in the option and shares issuable upon exercise.

Context This was a director compensation-related option award (a derivative grant), not an outright share purchase or sale. Because Fleming disclaims beneficial ownership and the award is held for Enavate Sciences, the grant effectively benefits that entity rather than indicating Fleming’s personal accumulation of UPB stock. Derivative grants like this typically vest over time and do not represent immediately tradable shares until vested and exercised.